Please add info@sitcancer.org to your safe senders list. |
Support SITC Membership Meetings About SITC www.sitcancer.org |
Don't miss the opportunity to weigh in on SITC's 2016 Advances in Cancer ImmunotherapyTM series locations! Learn more. June 2015 - In this Issue Society Updates | Education & Events | Society Journal | Careers A Message from the PresidentDear Colleagues, June is a month dedicated to celebrating advances in cancer immunotherapy worldwide. This year, more than ever before, cancer immunotherapy has positioned itself at the forefront of the oncology field, taking center stage at the American Society of Clinical Oncology (ASCO) Annual Meeting where it was clear that patients with a variety of cancers were achieving clinical benefit. As stakeholders in the field, we understand how critical clinical trials are to advancing the knowledge of cancer immunotherapy and improving outcomes for patients. While several cancer immunotherapies have received FDA approval in recent years—representing a new hope for patients—many more approaches, including combination strategies, are still under development and being tested in clinical trials. The Society for Immunotherapy of Cancer (SITC) maintains that collaboration and discussion surrounding clinical trials in progress is crucial to developing a greater understanding of how immunotherapies work and for whom they work best. To foster this dialogue, SITC is currently accepting abstracts for Clinical Trials in Progress. Accepted abstracts will be eligible for poster or oral presentation at the SITC 30th Anniversary Annual Meeting and will be published in the Journal for ImmunoTherapy of Cancer (JITC), making the research accessible on a global scale. In fact, in this month’s JITC digest, Editor-in-Chief Dr. Pedro Romero announced a new Clinical Trials Monitor section—led by Dr. Leisha Emens—that promises to provide perspectives on and implications of late-stage pivotal clinical trial results and new regulatory approvals, in addition to providing announcements and updates on clinical trials in progress. I thank each of you for your work to advance the field—during Cancer Immunotherapy Month and always. Together, we can “white out cancer.” Sincerely, Howard L. Kaufman, MD, FACS Society UpdatesStakeholders from Around the Globe Raise Awareness to #WhiteOutCancer Day is an awareness and fundraising event for which people across the globe wear white in support of Cancer Immunotherapy Month. In support of this event, the SITC team took to Twitter with CURE photos that captured the attention of members and nonmembers alike. With numerous favorites and retweets, SITC's awareness-raising activities were a great success. Get ready for next year’s #WhiteOutCancer Day—and show your support for cancer immunotherapy research every day—by purchasing a CURE t-shirt. Proceeds benefit the next generation of cancer immunotherapy experts through travel awards and fellowships provided by the ForwardFund.
Education & EventsShowcase Your Science at SITC 2015 – Submit Your Abstract Today Submit your abstract to SITC's 30th Anniversary Annual Meeting by Thursday, July 9 at 5 p.m. EDT to be considered for poster and oral presentation slots! Additional benefits of abstract acceptance include publication in the Journal for ImmunoTherapy of Cancer and consideration for one of 30 Abstract Travel Awards for young investigators. Learn more and submit your abstract here.
Tumor Immunology 101: A Navigation Guide for the Growing Field of Cancer Immunotherapy is Coming to a City Near You Presented by leading authorities in tumor immunology and cancer immunotherapy, all Advances in Cancer ImmunotherapyTM series CME- and CNE-certified programs provide attendees with an understanding of cancer immunotherapies, their therapeutic effectiveness and the appropriate selection and management of patients. Clinical oncologists, registered nurses, nurse practitioners and the entire medical team involved in treating cancer patients are encouraged to attend. Reserve your spot at one of the locations listed below!
Get more information, including session topics and accreditation details, here. Interested in hosting an ACI program in your community? Let us know by completing this quick online survey! Physician Continuing Medical Education Get Published in the Journal for ImmunoTherapy of CancerThe Journal for ImmunoTherapy of Cancer (JITC), SITC's own open access, peer-reviewed journal, is a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application. SITC will once again be offering two $1,000 USD awards for the best papers submitted in the Clinical/Translational and Basic Science categories. To be eligible, papers must be published in JITC by August 18, 2015. In addition, SITC members are encouraged to take advantage of waived article processing charges for manuscripts accepted in 2015—a $2,500 value! Submit your manuscript here. Latest Career Opportunities from SITC's Job BoardOther Listings on SITC's Job Board Research Scientist I/II, Fibrosis - Oncology/Inflammation Biology Associate Scientist, Oncology Biomarkers Post-Doctoral Scientist, HIV Immunology Sr. Scientist, Biologics & Target Biology Sr. Research Scientist I, Oncology - Biomarkers If you are interested in posting an open position to SITC's job board, please reference this agreement form for posting criteria or contact SITC at info@sitcancer.org. |
Society for Immunotherapy of Cancer (SITC) © 2015 Society for Immunotherapy of Cancer Join us on: You have received this message because you have had previous contact with the Society for Immunotherapy of Cancer. If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line. Please add info@sitcancer.org to your safe senders list. |